Search

This article sets out a data-driven approach for targeting environmental policies optimally in order to combat deforestation. We focus on the Amazon, the world's most extensive rainforest, where Brazil's federal government issued a "Priority List" of municipalities in 2008—a blacklist to be targeted with more intense environmental monitoring and enforcement. First, we estimate the causal impact of the Priority List on deforestation (along with other relevant treatment effects) using "changes-in-changes" due to Athey and Imbens (2006), finding that it reduced deforestation by 43 |$\%$| and cut emissions by almost 50 million tons of carbon. Second, we develop a novel framework for computing targeted optimal blacklists that draws on our treatment effect estimates, assigning municipalities to a counterfactual list that minimizes total deforestation subject to realistic resource constraints. We show that the ex post optimal list would result in carbon emissions over 10 |$\%$| lower than the actual list, amounting to savings of more than |$ \$ $| 1.2 billion (34 |$\%$| of the total value of the Priority List), with emissions over 23 |$\%$| lower on average than a randomly selected list. The approach we propose is relevant both for assessing targeted counterfactual policies to reduce deforestation and for quantifying the impacts of policy targeting more generally. [ABSTRACT FROM AUTHOR]

Background: Cholangiocarcinoma management is constantly being updated in view of existing evidence in order to establish practice guidelines and consensus statements. However, the available treatment guidelines to optimize outcomes for cholangiocarcinoma patients who require liver transplantation are still controversial. This study contributing to the cholangiocarcinoma care field by investigating a new promising neoadjuvant therapy that might be help to grant the liver transplant option to the patients with cholangiocarcinoma. Here, we evaluate and compare the potential efficacy of chemotherapy combination of Gemcitabine plus Cisplatin versus non- Gemcitabine and Cisplatin regimens as a neo-adjuvant treatment for cholangiocarcinoma patients prior to liver transplantation. Methods: In this retrospective study, patients with locally advanced, unresectable, hilar, or intrahepatic cholangiocarcinoma with no evidence of extrahepatic disease or vascular involvement were treated with either the combination of neo-adjuvant Gemcitabine plus Cisplatin with no radiation or other standard options of neo-adjuvant treatment. All patients included received chemotherapy prior to being listed for liver transplantation at a single cancer center in collaboration with the same institution's transplant center according to an open-labeled, and centers-approved clinical management protocol. Patients were listed for liver transplantation if they had a minimum of six months of scans showing response or confirmation of disease stability. The primary endpoints were the overall survival and recurrence-free survival after liver transplantation. This report, which was censored on March 18, 2022. Results: Out of a total of 707 liver transplant recipients were screened, 37 patients were confirmed with a diagnosis of cholangiocarcinoma and only 18 patients (11 males and 7 females) with a median age of 61.83 [interquartile range: 58.27-68.74] met inclusion criteria. Of the 18 patients enrolled, 10 received Gemcitabine/Cisplatin, while 8 patients received either Gemcitabine monotherapy or Capecitabine or FOLFIRI. Months for recurrence after transplantation was 20.1 (IRQ: 20.1-20.1) in the Gemcitabine/Cisplatin group and 9.5 (8.9-12.47) months in the non-Gemcitabine/Cisplatin group (p-value=0.18). Median months of follow-up in the Gemcitabine/Cisplatin group was 28.35 (27.1-32.23) months versus 40.12 (20.6-56.22) months in the non-Gemcitabine/Cisplatin group (p-value=0.33). In non-Gemcitabine/Cisplatin patients, overall survival was 75% (95% CI 31-93%) at both years 1 and 2; 63% (95% CI 23-86%) at years 3 to 5. In Gemcitabine/Cisplatin patients, overall survival was 100% (95% CI 100-100%) at both years 1 and 2; 75% (95% CI 13-96%) at years 3 to 5. Three non-Gemcitabine/Cisplatin patients died at 328 days, 340 days, and 896 days, respectively. One Gemcitabine/Cisplatin patient died at 885 days. Conclusion: Our findings suggest improved overall survival outcomes with Gemcitabine plus Cisplatin as neo-adjuvant treatment with no concomitant radiation compared to non-Gemcitabine/Cisplatin regimens in patients with cholangiocarcinoma prior to liver transplantation. [ABSTRACT FROM AUTHOR]

Background: The management of cholangiocarcinoma is continually reviewed on a current evidence basis to develop practice guidelines and consensus statements. However, the standardized treatment guidelines are still unclear for cholangiocarcinoma patients who are listed for liver transplantation. We aimed to validate and evaluate the potential efficacy of chemotherapy combination of Gemcitabine and Cisplatin as a neo-adjuvant treatment for cholangiocarcinoma patients before liver transplantation. Methods: In this prospective case series, patients with locally advanced, unresectable, hilar, or intrahepatic cholangiocarcinoma with no evidence of extrahepatic disease or vascular involvement were treated with a combination of neoadjuvant gemcitabine and cisplatin with no radiation. All patients included received chemotherapy prior to being listed for liver transplantation at a single cancer center according to an open-labeled, and center-approved clinical management protocol. The primary endpoints were the overall survival and recurrence-free survival after liver transplantation. Results: Between 1 March 2016, and 15 March 2022, 10 patients (8 males and 2 females) with a median age of 62.71(interquartile range: 60.02–71.87) had a confirmed diagnosis of intrahepatic or hilar cholangiocarcinoma and underwent liver transplantation. Median days of neoadjuvant therapy for a given combination of gemcitabine and cisplatin were 181 (IRQ: 120–250). Nine patients (90%) were reported with no recurrence or metastasis, and only 1 patient had confirmed metastasis (10%); days for metastasis after transplantation were 612 for this patient. All patients received a combination of gemcitabine and cisplatin as neo-adjuvant while awaiting liver transplantation. The median days of follow-up were 851 (813–967). Overall survival was 100% (95% CI 100–100%) at both years one and two; 75% (95% CI 13–96%) at years three to five. One patient died at eight hundred and eighty-five days. No adverse events were reported after liver transplantation including the patient who was confirmed with recurrence. Conclusions: Our finding demonstrated that neo-adjuvant gemcitabine and cisplatin with no radiation prior to liver transplantation resulted in excellent outcomes for patients with cholangiocarcinoma. [ABSTRACT FROM AUTHOR]

The safety and efficacy of treatment with a novel thrombopoiesis-stimulating protein, AMG 531 (Amgen), in patients with immune thrombocytopenic purpura (ITP) are evaluated. The results have shown that AMG 531 caused no major adverse events and increased platelet counts in patients with ITP.

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.euroecorev.2004.10.007 Byline: Sajid Anwar (a)(b), Robert McMillan (c), Mingli Zheng (d) Abstract: Much of the existing auction literature treats auctions as running independently of one another, with each bidder choosing to participate in only one auction. However, in many online auctions, a number of substitutable goods are auctioned concurrently and bidders can bid on several auctions at the same time. Recent theoretical research shows how bidders can gain from the existence of competing auctions, the current paper providing the first empirical evidence in support of competing auctions theory using online auctions data from eBay. Our results indicate that a significant proportion of bidders do bid across competing auctions and that bidders tend to submit bids on auctions with the lowest standing bid, as the theory predicts. The paper also shows that winning bidders who cross-bid pay lower prices on average than winning bidders who do not. Author Affiliation: (a) School of Business, James Cook University, P.O. Box 6811, Cairns, QLD 4870, Australia (b) IGSM University of South Australia, Adelaide, SA 5000, Australia (c) Department of Economics, University of Toronto, Toronto, Ontario M5S 3G7, Canada (d) Faculty of Social Sciences and Humanities, University of Macau, Taipa, Macau, China Article History: Received 25 February 2003; Accepted 4 October 2004 Article Note: (footnote) [star] This paper is based on Chapter 1 of Mingli Zheng's 2002 University of Toronto PhD thesis.

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jue.2004.06.002 Byline: Patrick Bayer (a), Robert McMillan (b), Kim S. Rueben (c) Keywords: Residential segregation; Racial segregation; Sorting; Housing markets Abstract: Using restricted Census microdata that link households to the Census block in which they live, this paper re-examines the question of whether racial differences in sociodemographic characteristics can explain observed levels of racial segregation. We develop a simple measurement framework designed to make use of the rich joint distribution of individual and neighborhood characteristics that these data provide, analyzing segregation patterns in the San Francisco Bay Area. The results indicate that racial differences in the collective set of characteristics we consider do have the potential to explain a considerable amount of the observed segregation, although more so for Asians and especially Hispanics than whites and blacks. Different sociodemographic factors emerge as potentially important for each race. Author Affiliation: (a) Department of Economics, Yale University, 37 Hillhouse Avenue, New Haven, CT 06511, USA (b) Department of Economics, University of Toronto, 150 St George Street, Toronto, ON, M5S 3G7, Canada (c) Public Policy Institute of California, 500 Washington Street, San Francisco, CA 94111, USA Article History: Received 13 August 2003; Revised 2 June 2004

The effect of incentives in promoting quality of public schools under increased competition from private schools is examined.

Asteroid pairs are genetically related asteroids that recently separated (